These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 37750426)
1. Is galectin-3 a useful biomarker in stratifying the risk of heart failure in diabetes? Cuspidi C; Gherbesi E; Faggiano A J Clin Ultrasound; 2023; 51(9):1436-1438. PubMed ID: 37750426 [No Abstract] [Full Text] [Related]
2. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. French B; Wang L; Ky B; Brandimarto J; Basuray A; Fang JC; Sweitzer NK; Cappola TP J Card Fail; 2016 Apr; 22(4):256-62. PubMed ID: 26571149 [TBL] [Abstract][Full Text] [Related]
3. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD; Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625 [TBL] [Abstract][Full Text] [Related]
4. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction. Sandesara PB; O'Neal WT; Kelli HM; Samman-Tahhan A; Hammadah M; Quyyumi AA; Sperling LS Diabetes Care; 2018 Jan; 41(1):150-155. PubMed ID: 29051160 [TBL] [Abstract][Full Text] [Related]
5. Galectin-3 in Heart Failure: An Update of the Last 3 Years. Gehlken C; Suthahar N; Meijers WC; de Boer RA Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers of heart failure with normal ejection fraction: a systematic review. Cheng JM; Akkerhuis KM; Battes LC; van Vark LC; Hillege HL; Paulus WJ; Boersma E; Kardys I Eur J Heart Fail; 2013 Dec; 15(12):1350-62. PubMed ID: 23845797 [TBL] [Abstract][Full Text] [Related]
7. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. de Boer RA; Lok DJ; Jaarsma T; van der Meer P; Voors AA; Hillege HL; van Veldhuisen DJ Ann Med; 2011 Feb; 43(1):60-8. PubMed ID: 21189092 [TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of biomarkers in chronic heart failure with preserved left ventricular ejection fraction]. Nikiforova TA; Shchekochikhin DY; Kopylov FY; Syrkin AL Ter Arkh; 2016; 88(9):102-105. PubMed ID: 28635812 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Carrasco-Sánchez FJ; Aramburu-Bodas O; Salamanca-Bautista P; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio MI; Arias-Jiménez JL; Aguayo-Canela M; Pérez-Calvo JI Int J Cardiol; 2013 Nov; 169(3):177-82. PubMed ID: 24207066 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Polat V; Bozcali E; Uygun T; Opan S; Karakaya O Acta Cardiol; 2016 Apr; 71(2):191-7. PubMed ID: 27090041 [TBL] [Abstract][Full Text] [Related]
11. N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trial. Sani MU; Damasceno A; Davison BA; Cotter G; Mayosi BM; Edwards C; Azibani F; Adam T; Arif G; Jessen N; Sliwa K ESC Heart Fail; 2021 Feb; 8(1):74-84. PubMed ID: 33247624 [TBL] [Abstract][Full Text] [Related]
12. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Srivatsan V; George M; Shanmugam E Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020 [TBL] [Abstract][Full Text] [Related]
13. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing. Carrasco-Sánchez FJ; Páez-Rubio MI Mol Diagn Ther; 2014 Dec; 18(6):599-604. PubMed ID: 24989720 [TBL] [Abstract][Full Text] [Related]
14. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Rabkin SW; Tang JKK Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523 [TBL] [Abstract][Full Text] [Related]
15. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952 [TBL] [Abstract][Full Text] [Related]
16. Practical experience using galectin-3 in heart failure. McCullough PA Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562 [TBL] [Abstract][Full Text] [Related]
17. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877 [TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. De Marco C; Claggett BL; de Denus S; Zile MR; Huynh T; Desai AS; Sirois MG; Solomon SD; Pitt B; Rouleau JL; Pfeffer MA; O'Meara E ESC Heart Fail; 2021 Apr; 8(2):1130-1138. PubMed ID: 33438360 [TBL] [Abstract][Full Text] [Related]
19. Impact of diabetes on the predictive value of heart failure biomarkers. Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845 [TBL] [Abstract][Full Text] [Related]
20. Galectin-3 in heart failure with preserved ejection fraction. de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]